BN Business News
Add your company to Business Communicator →

Business · 06/11/2023

FDA Clears Path for FORADIL Inhalation Powder Approval

The FDA has determined that FORADIL inhalation powder, 0.012 mg/inh, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of formoterol fumarate inhalation powder through abbreviated new drug applications.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights